

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/58895 A1

(51) International Patent Classification⁷: C07D 405/12,
413/12, 405/14, 413/14, A61K 31/41, 31/415, 31/42,
A61P 29/00

John, Gary; Celltech R & D Ltd, Granta Park, Great
Abington, Cambridge CB1 6GS (GB).

(21) International Application Number: PCT/GB01/00518

(74) Agent: GILL JENNINGS & EVERY; Broadgate House,
7 Eldon Street, London EC2M 7LH (GB).

(22) International Filing Date: 8 February 2001 (08.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0003257.3 11 February 2000 (11.02.2000) GB

(71) Applicant: DARWIN DISCOVERY LIMITED
[GB/GB]: 216 Bath Road, Slough, Berks SL1 4EN
(GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.





(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: DYKE, Hazel, Joan; Celltech R & D Ltd,
Granta Park, Great Abington, Cambridge CB1 6GS (GB).
LOWE, Christopher; Celltech R & D Ltd, Granta Park,
Great Abington, Cambridge CB1 6GS (GB). MONTANA,

Published:
— with international search report

[Continued on next page]

(54) Title: BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE



(57) Abstract: A compound of the formula (i) wherein R₁ is C₁₋₃ alkyl optionally substituted with one or more fluorines; R₂ is CH₂OCH₃ or 2 or 3-tetrahydrofuryl; R₃ is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C); R₄ is C₁₋₃ alkyl; and R₅ and R₆, which may be the same or different, each represents C₁₋₃ alkyl, halogen, CF₃ or CN; or a pharmaceutically-acceptable salt thereof.

WO 01/58895 A1



— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

BENZOFURAN CARBOXAMIDES AND THEIR THERAPEUTIC USE

Field of the Invention

The present invention relates to novel heterocyclic compounds and to their formulation and use as pharmaceuticals.

5. Background of the Invention


The modes of action of phosphodiesterases and also tumour necrosis factor (TNF), and the therapeutic utilities of inhibitors thereof, are described in WO-A-97/44337 and US Patents Nos. 5925636 and 5972936, the contents of which are incorporated herein by reference. These reference describe benzofurans having such activity.

10 Summary of the invention

This invention provides novel compounds having therapeutic utility, in particular for the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting TNF and/or PDE IV. According to the invention, the compounds are of formula (i):

15

20




wherein R_1 is C_{1-3} alkyl optionally substituted with one or more fluorines;

25

R_2 is CH_2OCH_3 or 2 or 3-tetrahydrofuranyl;

R_3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C)

30



R_4 is C_{1-3} alkyl; and
 R_5 and R_6 , which may be the same or different, each represents C_{1-3} alkyl, halogen, CF_3 or CN ,
or a pharmaceutically-acceptable salt thereof.

5 In summary, the compounds of the invention represent a selection within the scope of WO-A-97/44337. The novel compounds have superior *in vivo* activity.

This invention provides also a method for mediating or inhibiting the enzymatic activity or catalytic activity of PDE IV in a mammal in need thereof and for inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said
10 mammal an effective amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof.

Description of the Invention

The term " C_{1-3} alkyl" means methyl, ethyl, propyl or isopropyl.

One group of compounds of the invention is of formula (i) in which R_1 is CH_3 or
15 CHF_2 .

R_3 may in particular be a pyrazole of partial formula (A) or an isoxazole of partial formula (C). When R_3 is a pyrazole moiety, R_4 is especially CH_3 and R_5 is particularly CN , CH_3 , Cl or CF_3 . Where R_3 is an isoxazole moiety, R_5 is especially CH_3 , CF_3 or CN and R_6 is particularly CH_3 , CF_3 or CN .

20 The compounds of the Examples are especially preferred.


It will be appreciated by those skilled in the art that compounds of formula (i) in which R_2 represents tetrahydrofuran contain a chiral centre. This invention extends to both enantiomers and all mixtures thereof, including racemic mixtures.

Certain of the compounds of formula (i) which contain a basic group form acid
25 addition salts. Suitable acid addition salts include pharmaceutically-acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide, and pharmaceutically-acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphate, α -ketoglutarate, α -glycerophosphate and glucose-1-phosphate. The pharmaceutically-acceptable salts of
30 the compounds of formula (i) are prepared using conventional procedures.


Compounds of the invention may be prepared by reaction of an appropriate carboxylic acid of formula (ii) with a suitable amine of formula (iii) as described in WO

97/44337. Carboxylic acids of formula (ii) may be conveniently prepared from compounds of formula (iv) by bromination followed by palladium-catalysed carbonylation as described in WO 97/44337. Amines of formula (iii) are either commercially available, previously described compounds, or are prepared using standard conditions known to those skilled in the art.


Compounds of formula (iv) in which R_1 represents methyl and R_2 represents CH_2OCH_3 may be conveniently prepared from o-vanillin as shown below. o-Vanillin is treated with bromoacetaldehyde dimethyl acetal in the presence of a base, such as potassium carbonate, in a suitable solvent such as N,N-dimethylformamide, favourably at elevated temperature. The resultant acetal can then be cyclised, for example by heating in acetic acid, to provide 7-methoxybenzofuran-2-carbaldehyde. The aldehyde may be reduced using any suitable reducing agent known to those skilled in the art, such as sodium borohydride. The resultant alcohol may be methylated using any appropriate methylating agent, such as methyl iodide, in the presence of an appropriate base, such as sodium hydride.



Compounds of formula (iv) in which R_1 represents methyl and R_2 represents 3-tetrahydrofuranyl may be prepared from 7-methoxybenzofuran as depicted below. 7-Methoxybenzofuran may be deprotonated by treatment with any suitable base, such as butyllithium, and the resultant anion added to tetrahydrofuran-3-one. The resultant alcohol may be converted to a leaving group, such as a mesylate, and then eliminated. The alkene thus formed may be reduced using any suitable reducing agent, such as Raney nickel and hydrogen.



Compounds of formula (iv) in which R_1 represents methyl and R_2 represents 2-tetrahydrofuranyl may be prepared from 7-methoxybenzofuran-2-carbaldehyde as shown below. A suitably protected Grignard reagent derived from 1,3-propanediol may be added to 7-methoxybenzofuran-2-carbaldehyde, and the protecting group may then be removed. A suitable protecting group may be *tert*-butyldimethylsilyl, which may be removed using any standard conditions known to those skilled in the art, for example tetrabutylammonium fluoride. Cyclisation of the resultant diol may be achieved using any appropriate conditions, such as *p*-toluenesulphonic acid and molecular sieves in a suitable solvent such as dichloromethane.



15

20

Compounds of formula (iv) in which R_1 represents difluoromethoxy may be prepared by demethylation, and subsequent difluoromethylation, of suitable intermediates in which R_1 represents methyl. Such demethylation may be carried out using any suitable conditions known to those skilled in the art. Suitable conditions

25

include the use of ethane thiolate in an appropriate solvent, such as *N,N*-dimethylformamide, at a suitable temperature. Suitable temperatures include elevated temperatures, favourably 140°C. Difluoromethylation of the resultant phenols may be carried out using any suitable conditions known to those skilled in the art. Suitable
5 conditions include the use of chlorodifluoromethane and a suitable base in an appropriate solvent at an appropriate temperature. Favourably, the reaction is conducted in dioxane as solvent using aqueous sodium hydroxide as base. Elevated temperatures, such as reflux temperature, may be employed.

The invention includes the prevention and treatment of TNF-mediated disease or
10 disease states, by which is meant any and all disease states in which TNF plays a role, either by production of TNF itself, or by TNF causing another cytokine to be released, such as but not limited to IL-1 or IL-6. A disease state in which IL-1, for instance, is a major component, and whose production or action is exacerbated or secreted in response to TNF, would therefore be considered a disease state mediated by TNF. As TNF- β (also
15 known as lymphotoxin) has close structural homology with TNF- α (also known as cachectin), and since each induces similar biological responses and binds to the same cellular receptor, both TNF- α and TNF- β are inhibited by compounds of the present invention and thus are herein referred to collectively as "TNF" unless specifically delineated otherwise.

20 PDE IV inhibitors are useful in the treatment of a variety of allergic and inflammatory diseases, including: asthma, chronic bronchitis, atopic dermatitis, atopic eczema, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, psoriasis, Bechet's disease, erythematosis, anaphylactoid purpura nephritis, joint inflammation,
25 arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis and osteoarthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome. In addition, PDE IV inhibitors are useful in the treatment of diabetes insipidus and conditions associated with cerebral metabolic inhibition, such as
30 cerebral senility, senile dementia (Alzheimer's disease), memory impairment associated with Parkinson's disease, depression and multi-infarct dementia. PDE IV inhibitors are also useful in conditions ameliorated by neuroprotectant activity, such as cardiac arrest, stroke

and intermittent claudication. Additionally, PDE IV inhibitors could have utility as gastroprotectants. A special embodiment of the therapeutic methods of the present invention is the treatment of asthma.

5 The viruses contemplated for treatment herein are those that produce TNF as a result of infection, or those which are sensitive to inhibition, such as by decreased replication, directly or indirectly, by the TNF inhibitors of Formula (i). Such viruses include, but are not limited to HIV-1, HIV-2 and HIV-3, cytomegalovirus (CMV), influenza, adenovirus and the Herpes group of viruses, such as, but not limited to, *Herpes*
10 *zoster* and *Herpes simplex*.

10 This invention more specifically relates to a method of treating a mammal, afflicted with a human immunodeficiency virus (HIV), which comprises administering to such mammal an effective TNF inhibiting amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof.

15 The compounds of this invention may be also be used in association with the veterinary treatment of animals, other than humans, in need of inhibition of TNF production. TNF mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted above, but in particular viral infections. Examples of such viruses include, but are not limited to feline immunodeficiency virus (FIV) or other retroviral infection such as equine infectious anaemia virus, caprine arthritis
20 virus, visna virus, maedi virus and other lentiviruses.

The compounds of this invention are also useful in treating parasite, yeast and fungal infections, where such yeast and fungi are sensitive to upregulation by TNF or will elicit TNF production *in vivo*. A preferred disease state for treatment is fungal meningitis.

The compounds of formula (i) are preferably in pharmaceutically-acceptable form.
25 By pharmaceutically-acceptable form is meant, *inter alia*, a pharmaceutically-acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. A pharmaceutically-acceptable level of purity will generally be at least 50% excluding normal pharmaceutical additives, preferably 75%, more preferably 90% and still more preferably 95%. When
30 used herein the term "pharmaceutically-acceptable" encompasses materials suitable for both human and veterinary use.

A compound of formula (i) or where appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, may be administered *per se* or, preferably, as a pharmaceutical composition also comprising a pharmaceutically-acceptable carrier.

5 Accordingly, the present invention provides a pharmaceutical composition comprising a compound of formula (i) or where appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, and a pharmaceutically-acceptable carrier.

10 The active compound may be formulated for administration by any suitable route, the preferred route depending upon the disorder for which treatment is required, and is preferably in unit dosage form or in a form that a human patient may administer to himself in a single dosage. Advantageously, the composition is suitable for oral, rectal, topical, parenteral administration or through the respiratory tract. Preparations may be designed to give slow release of the active ingredient.

15 The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc, the compounds of the invention are effective in the treatment of humans.

20 The compositions of the invention may be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. Topical formulations are also envisaged where appropriate.

25 In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose. Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example microcrystalline cellulose, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically-acceptable wetting agents such as sodium lauryl sulphate.

30

Solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers.

Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.

Oral liquid preparations may be in the form of, for example, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia, non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.

Compositions may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebuliser, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 μm , such as from 0.1 to 50 μm , preferably less than 10 μm , for example from 1 to 10 μm , 1 to 5 μm or from 2 to 5 μm . Where appropriate, small amounts of other anti-asthmatics and bronchodilators for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine; corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved in water for injection and filter-sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be

frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration.

Compounds of formula (i), or if appropriate a pharmaceutically-acceptable salt thereof and/or a pharmaceutically-acceptable solvate thereof, may also be administered as a topical formulation in combination with conventional topical excipients.

Topical formulations may be presented as, for instance, ointments, creams or lotions, impregnated dressings, gels, gel sticks, spray and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams. The formulations may contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.

Suitable cream, lotion, gel, stick, ointment, spray or aerosol formulations that may be used for compounds of formula (i) or if appropriate a pharmaceutically-acceptable salt thereof, are conventional formulations well known in the art, for example, as described in standard text books such as Harry's Cosmeticology published by Leonard Hill Books, Remington's Pharmaceutical Sciences, and the British and US Pharmacopoeias.

Suitably, the compound of formula (i), or if appropriate a pharmaceutically-acceptable salt thereof, will comprise from about 0.5 to 20% by weight of the formulation, favourably from about 1 to 10%, for example 2 to 5%.

The dose of the compound used in the treatment of the invention will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and the relative efficacy of the compound. However, as a general guide suitable unit doses may be 0.1 to 1000 mg, such as 0.5 to 200, 0.5 to 100 or 0.5 to 10 mg, for example 0.5, 1, 2, 3, 4 or 5 mg; and such unit doses may be administered more than once a day, for example 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total daily dosage for a 70 kg adult is in the range of about 0.1 to 1000 mg, that is in the range of about 0.001

to 20 mg/kg/day, such as 0.007 to 3, 0.007 to 1.4, 0.007 to 0.14 or 0.01 to 0.5 mg/kg/day, for example 0.01, 0.02, 0.04, 0.05, 0.06, 0.08, 0.1 or 0.2 mg/kg/day, and such therapy may extend for a number of weeks or months.

Assay Methods

5 The assays used to confirm the phosphodiesterase IV inhibitory activity of compounds of formula (I) are standard assay procedures as disclosed by Schilling *et al*, Anal. Biochem. 216:154 (1994), Thompson and Strada, Adv. Cycl. Nucl. Res. 8:119 (1979) and Gristwood and Owen, Br. J. Pharmacol. 87:91P (1986).

10 Compounds of formula (i) have exhibited activity at levels consistent with those believed to be useful in treating phosphodiesterase IV related disease states in those assays.

The ability of compounds of formula (i) to inhibit TNF production in human peripheral blood mononuclear cells (PMBC's) is measured as follows. PMBC's are prepared from freshly taken blood or "Buffy coats" by standard procedures. Cells are
15 plated out in RPMI1640 +1% foetal calf serum in the presence and absence of inhibitors. LPS (Lipopolysaccharide (endotoxin); 100 ng/ml) is added and cultures are incubated for 22 h at 37°C in an atmosphere of 95% air/5% CO₂. Supernatants are tested for TNF α by ELISA (Enzyme linked immunosorbent assay) using commercially available kits.

Activity in a guinea pig lung model is measured using the procedures described by
20 Mauser *et al*, Am. Rev. Respir. Dis. 148:1623 (1993), and Am. J. Respir. Crit. Care Med. 152:467 (1995).

The compound of Example 2 of WO-A-97/44337 exhibits 41% inhibition of eosinophilia in the guinea pig model when dosed at 30 mg/kg. Example 10 herein (representative of the present invention) achieves 35% inhibition when dosed at 3 mg/kg.

25 The following Examples illustrate the invention.

Intermediate 1 2-(2-Formyl-6-methoxyphenoxy)acetaldehyde, dimethyl acetal

o-Vanillin (20g) and potassium carbonate (18g) were stirred in *N,N*-dimethylformamide (80ml) at room temperature for 30 minutes. Bromoacetaldehyde dimethyl acetal (24g) was added dropwise ensuring that the temperature did not rise above
30 50°C. The mixture was then heated at reflux for 4 hours then cooled to room temperature. Diethyl ether (30ml) was added and the mixture was filtered. The solid was

washed with ether (2 x 30ml) and the combined organic phases were concentrated *in vacuo* to give the title compound (33g) as a green oil.

TLC R_f 0.66 (50% ethyl acetate in hexane).

Intermediate 2 **7-Methoxybenzofuran-2-carbaldehyde**

- 5 2-(2-Formyl-6-methoxyphenoxy)acetaldehyde, dimethyl acetal (31g) was heated to reflux in glacial acetic acid (120ml) overnight. The mixture was then cooled and the solvent removed *in vacuo* to give a red oil. Purification by Kugelrohr distillation gave the title compound (17g) as a pale yellow oil which solidified on standing.

TLC R_f 0.71 (dichloromethane).

10 **Intermediate 3** **7-Methoxybenzofuran-2-yl-methanol**

Sodium borohydride (0.462g) was added in one portion to a stirred solution of 7-methoxybenzofuran-2-carbaldehyde (2.15g) in methanol (50ml) at room temperature and the reaction was stirred for 3 hours. The reaction mixture was then diluted with water (100ml) and extracted with dichloromethane (3x30ml). The organic extracts were

- 15 combined, washed with water (30ml), dried over magnesium sulphate, filtered and the solvent removed *in vacuo* to afford the title compound (2.10g) as a pale orange liquid.

TLC R_f 0.51 (2% methanol in dichloromethane).

Intermediate 4 **7-Methoxy-2-methoxymethylbenzofuran**

Sodium hydride (3.82g, 60% in mineral oil) was added to a solution of 7-methoxybenzofuran-2-ylmethanol (11.21g) in dry tetrahydrofuran (300ml) under an atmosphere of dry nitrogen at room temperature. After 10 minutes iodomethane (15.67ml) was added and the reaction was left to stir overnight. The solvent was removed *in vacuo* and the residue partitioned between ethyl acetate (100ml) and water (50ml). The organic extract was washed with water (50ml), followed by brine (50ml), dried over magnesium sulphate,

- 25 filtered and the solvent removed *in vacuo* to afford the title compound (13.32g) as a yellow oil.

TLC R_f 0.70 (50% ethyl acetate in hexane).

Intermediate 5 **4-(tert-Butyldimethylsilyloxy)-1-(7-methoxybenzofuran-2-yl)-butan-1-ol**

- 30 A suspension of dried magnesium turnings (0.42g) in anhydrous tetrahydrofuran (20ml) was treated with 2ml of (3-Bromopropoxy)-tert-butyldimethylsilane (4.4g) in anhydrous tetrahydrofuran (10ml) at room temperature under a dry nitrogen atmosphere.

Initiation was achieved by the addition of catalytic iodine and warming to 80°C. The remaining solution (8ml) was then added carefully. The reaction was cooled to -5°C and a solution of 7-methoxybenzofuran-2-carbaldehyde (3g) in anhydrous tetrahydrofuran (20ml) was added carefully. After stirring at ambient temperature overnight the solvent was removed *in vacuo*. The residue was partitioned between ethyl acetate (100ml) and saturated aqueous ammonium chloride solution (100ml). The organic extract was dried over magnesium sulphate, filtered and preadsorbed onto silica. Purification by column chromatography on silica eluting with 10% ethyl acetate in hexane afforded the title compound as a yellow oil (4.88g).

10 TLC R_f 0.75 (20% ethyl acetate).

Intermediate 6 1-(7-Methoxybenzofuran-2-yl)-butane-1,4-diol

Tetrabutylammonium fluoride (12ml, 1M in tetrahydrofuran) was added to a stirred solution of 4-(*tert*-butyldimethylsilyloxy)-1-(7-methoxybenzofuran-2-yl)-butan-1-ol (4g) in tetrahydrofuran (50ml) at 0°C. After stirring cooled for 2 hours the reaction was warmed to room temperature and allowed to stir for a further 1 hour. The solvent was removed *in vacuo* and the residue partitioned between ethyl acetate (100ml) and water (50ml). The organic extract was dried over magnesium sulphate, filtered and preadsorbed onto silica. Purification by column chromatography on silica eluting with ethyl acetate yielded the title compound as a tan oil (2.34g).

20 TLC R_f 0.15 (50% ethyl acetate in hexane).

Intermediate 7 7-Methoxy-2-(tetrahydrofuran-2-yl)-benzofuran

A solution of 1-(7-methoxybenzofuran-2-yl)-butane-1,4-diol (0.88g) was treated with *p*-toluenesulfonic acid monohydrate (10mg) and 3Å molecular sieves in dichloromethane (10ml) at ambient temperature. After stirring for 1 hour the solvent was removed *in vacuo*. The residue was purified by column chromatography on silica eluting with 20% ethyl acetate in hexane to give the title compound as a yellow oil (0.58g).

TLC R_f 0.35 (20% ethyl acetate in hexane).

Intermediate 8 3-(7-Methoxybenzofuran-2-yl)-tetrahydrofuran-3-ol

Methyl sulfoxide (1.16ml) was added dropwise to a stirred solution of oxalyl chloride (0.71ml) in dry dichloromethane (15ml) at -60°C under an inert atmosphere. After stirring at this temperature for 30 minutes a solution of 3-hydroxytetrahydrofuran (0.55ml) in dry dichloromethane was added carefully. After a further 30 minutes

triethylamine was added dropwise and the reaction allowed to warm to room temperature. The reaction was poured onto water (40ml) and extracted with dichloromethane (30ml). The organic phase was washed with water (50ml), brine (2x50ml) and saturated aqueous sodium hydrogen carbonate solution (2x50ml). After drying over magnesium sulphate the solvent was removed *in vacuo* to afford tetrahydro-furan-3-one as a yellow gum (0.19g). n-Butyllithium (0.72ml, 1.6M in hexanes) was added dropwise to a stirred solution of 7-methoxybenzofuran (0.15g) in dry tetrahydrofuran (5ml) at -78°C under a dry nitrogen atmosphere. After stirring for 20 minutes a solution of tetrahydrofuran-3-one (90mg) in dry tetrahydrofuran (2ml) was added carefully. After stirring for a further 15 minutes at -78°C the reaction was allowed to warm to room temperature. The reaction was carefully quenched with water and the solvent removed *in vacuo*. The residue was partitioned between ethyl acetate (2x15ml) and water (15ml). The combined organic extracts were dried over magnesium sulphate, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica eluting with 50% ethyl acetate in hexane to give the title compound as an orange gum (64mg). TLC R_f 0.37 (50% ethyl acetate in hexane).

Intermediate 9 7-Methoxy-2-(tetrahydrofuran-3-yl)-benzofuran

Triethylamine (0.19ml) was added to a stirred solution of 3-(7-methoxybenzofuran-2-yl)-tetrahydrofuran-3-ol (0.15g) in dry dichloromethane (8ml) at room temperature under a dry nitrogen atmosphere. Methanesulfonyl chloride (0.08ml) was then added followed by a catalytic amount of 4-(dimethylamino)pyridine. After stirring at room temperature overnight the solvent was removed *in vacuo*. The residue was purified by column chromatography on silica eluting with 50% ethyl acetate in hexane to give a mixture of 2-(4,5-dihydrofuran-3-yl)-7-methoxybenzofuran and 2-(2,5-dihydrofuran-3-yl)-7-methoxybenzofuran (85mg) as a yellow solid.

A solution of the alkene mixture (85mg) in ethanol (10ml) was treated with Raney Nickel and hydrogenated at atmospheric pressure for 1 hour. The reaction mixture was filtered through celite and the solvent was removed *in vacuo* to give the title compound as a white solid (80mg). TLC R_f 0.49 (33% ethyl acetate in hexane).

Intermediate 10 **2-(Tetrahydrofuran-3-yl)-benzofuran-7-ol**

Sodium hydride (0.19g, 60% in mineral oil) was added to a stirred solution of ethane thiol (0.34ml) in *N,N*-dimethylformamide (6ml) at room temperature under a dry nitrogen atmosphere. After stirring for 15 minutes 7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran (0.5g) in *N,N*-dimethylformamide (6ml) was added and the reaction heated to 140°C for 2 hours. After cooling to room temperature the solvent was removed *in vacuo*. The residue was partitioned between ethyl acetate (50ml) and water (50ml). The organic extract was dried over magnesium sulphate, filtered and preadsorbed onto silica. Purification by column chromatography on silica eluting with 50% ethyl acetate in heptane afforded the title compound as a brown oil (0.37g).
TLC R_f 0.38 (50% ethyl acetate in heptane).

Intermediate 11 ***tert*-Butyldimethyl-[2-(tetrahydrofuran-3-yl)-benzofuran-7-yloxy]-silane**

Sodium hydride (80mg, 60% dispersion in mineral oil) was added to a stirred solution of 2-(tetrahydrofuran-3-yl)-benzofuran-7-ol (0.37g) in dry tetrahydrofuran (10ml) at room temperature under a dry nitrogen atmosphere. After stirring for 10 minutes *tert*-butyldimethylsilyl chloride (0.27g) was added and the reaction stirred for 90 minutes. The reaction mixture was partitioned between ethyl acetate (30ml) and water (2x25ml). The combined aqueous washings were extracted with ethyl acetate (30ml). The organic extracts were combined, dried over magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a yellow oil (0.58g).
TLC R_f 0.7 (50% ethyl acetate in heptane).

Intermediate 12 **4-Bromo-7-methoxy-2-methoxymethylbenzofuran**

A solution of 7-methoxy-2-methoxymethylbenzofuran (13.32g) in acetonitrile (500ml) was stirred at room temperature. *N*-bromosuccinimide (11.04g) was added and stirring continued for 2 days after which the solvent was removed *in vacuo*. The resulting oil was partitioned between ethyl acetate (100ml) and sodium metasilicate solution (50ml), the organic extract washed with more sodium metasilicate solution (2x50ml), followed by brine (50ml). The organic layer was separated, dried over magnesium sulphate, filtered and the solvent removed *in vacuo* to afford the title compound as a yellow oil (18.61g).
TLC R_f 0.73 (50% ethyl acetate in hexane).

The following compounds were prepared in a similar manner.

Intermediate 13 **4-Bromo-7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran**

Starting from 7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran (0.58g). The title compound was obtained as a yellow oil (0.8g).

TLC R_f 0.35 (20% ethyl acetate in hexane).

5 **Intermediate 14** **4-Bromo-7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran**

Starting from 7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran (80mg). The title compound was obtained as a brown oil (65mg).

TLC R_f 0.46 (33% ethyl acetate in hexane).

Intermediate 15 **[4-Bromo-2-(tetrahydrofuran-3-yl)-benzofuran-7-yloxy]-tert-butyl dimethylsilane****10**

Starting from *tert*-Butyl dimethyl-[2-(tetrahydrofuran-3-yl)-benzofuran-7-yloxy]-silane (0.59g). Purification by column chromatography on silica eluting with 20% ethyl acetate in heptane afforded the title compound as a brown oil (0.31g).

TLC R_f 0.48 (20% ethyl acetate in heptane).

15 **Intermediate 16** **4-Bromo-2-(tetrahydrofuran-3-yl)-benzofuran-7-ol**

Tetrabutylammonium fluoride (8.1ml, 1M in tetrahydrofuran) was added to a stirred solution of [4-bromo-2-(tetrahydrofuran-3-yl)-benzofuran-7-yloxy]-*tert*-butyl dimethylsilane (2.69g) in dry tetrahydrofuran (80ml) at 0°C under a dry nitrogen atmosphere. After stirring at this temperature for 45 minutes the solvent was removed *in vacuo*. The residue was partitioned between ethyl acetate (75ml) and water (75ml). The organic extract was dried over magnesium sulphate, filtered and concentrated *in vacuo*. Purification by column chromatography on silica eluting with 50% ethyl acetate in heptane afforded the title compound as a clear oil (1g).

TLC R_f 0.39 (50% ethyl acetate in heptane).

25 **Intermediate 17** **4-Bromo-2-methoxymethylbenzofuran-7-ol**

To a stirred solution of sodium hydride (334mg, 60% in mineral oil) in dry *N,N*-dimethylformamide (25ml) under an atmosphere of dry nitrogen at room temperature was added dropwise ethane thiol (0.586ml). After stirring for 20 minutes a solution of 4-bromo-7-methoxy-2-methoxymethylbenzofuran (2.04g) in *N,N*-dimethyl-formamide (7ml) was added dropwise and the reaction mixture was heated at 160°C for 2 hours. The reaction was cooled and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (70ml) and washed with ammonium chloride solution (70ml). The organic extract

was dried over magnesium sulphate, filtered and the solvent removed *in vacuo*. Purification by column chromatography on silica eluting with 50% ethyl acetate in hexane afforded the title compound as a white solid (1.21g).

TLC R_f 0.65 (50% ethyl acetate in hexane).

5 **Intermediate 18** **4-Bromo-7-difluoromethoxy-2-methoxymethylbenzofuran**

To a solution of 4-bromo-2-methoxymethylbenzofuran-7-ol in 1,4-dioxane (25ml) heated to 100°C was added dropwise a solution of sodium hydroxide (0.76g) in water (2ml). Chlorodifluoromethane was bubbled through the reaction mixture for 2 hours after which it was allowed to cool to room temperature and the organic solvent removed *in vacuo*. The resulting aqueous slurry was extracted with ethyl acetate (3x25ml). The organic extracts were dried over magnesium sulphate, filtered and the solvent removed *in vacuo*. Purification by column chromatography on silica eluting with 20% ethyl acetate in hexane afforded the title compound as an off-white solid (1.24g). TLC R_f 0.73 (20% ethyl acetate in hexane).

15 The following compound was prepared in a similar manner.

Intermediate 19 **4-Bromo-7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran**

Starting from 4-bromo-2-(tetrahydrofuran-3-yl)-benzofuran-7-ol (1g). Purification by column chromatography on silica eluting with 30% ethyl acetate in heptane gave the title compound as a pale yellow solid (0.8g). TLC R_f 0.64 (50% ethyl acetate in heptane).

Intermediate 20 **7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid**

4-Bromo-7-methoxy-2-methoxymethylbenzofuran (18.61g), Pplladuim chloride (3.09g), bis-diphenylphosphinopropane (6.60g), triethylamine (49.65ml), tetrahydrofuran (200ml), and water (50ml) were combined in a Parr pressure reactor. The vessel was purged with carbon monoxide 3 times before being charged with carbon monoxide at 140psi. The vessel was then heated at 90°C for 3 days before cooling and release of the pressure. The reaction mixture was concentrated *in vacuo* and the residue taken up in 2N sodium hydroxide solution (250ml). The reaction mixture was washed with ethyl acetate (2x300ml) and then the aqueous layer was acidified to pH 5 with 10N hydrochloric acid. The resulting mixture was extracted with dicloromethane (2x100ml), the combined organic

extracts dried over magnesium sulphate, filtered and the solvent removed *in vacuo* to afford the title compound as a yellow solid (14.24g).

TLC R_f 0.31 (50% ethyl acetate in hexane).

The following compounds were prepared in a similar manner.

5 **Intermediate 21** **7-Difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid**

Starting from 4-bromo-7-difluoromethoxy-2-methoxymethylbenzofuran (1.24g). After carbonylation the reaction mixture was concentrated *in vacuo* to remove organic solvent and the subsequent aqueous residue extracted with dichloromethane (50ml). The aqueous layer was acidified to pH4 with glacial acetic acid and extracted with ethyl acetate (2x100ml). The combined organic extracts were dried over magnesium sulphate, filtered and the solvent removed *in vacuo* to afford the title compound as a white solid. TLC R_f 0.63 (50% ethyl acetate in hexane).

15 **Intermediate 22** **7-Methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid**

Starting from 4-bromo-7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran (1.9g). The title compound was obtained as an orange solid (1.18g). TLC R_f 0.58 (ethyl acetate).

20 **Intermediate 23** **7-Difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid**

Starting from 4-bromo-7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran (0.8g). The title compound was obtained as a cream solid (0.72g). TLC R_f 0.24 (50% ethyl acetate in heptane).

25 **Intermediate 24** **7-Methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid**

Starting from 4-bromo-7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran (0.8g). The title compound was obtained as an off white solid (0.63g). TLC R_f 0.13 (20% ethyl acetate in hexane).

30 **Intermediate 25** **7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid 4-nitrophenyl ester**

7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (0.42g), *p*-nitrophenol (0.29g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.4g) and 4-

dimethylaminopyridine (catalytic) in dry dichloromethane (30ml) were stirred overnight at room temperature. The reaction mixture was washed with water (40ml) and the aqueous layer extracted with dichloromethane (40ml). The organic extracts were combined, washed with water (80ml), dried over magnesium sulphate, filtered and the solvent removed *in vacuo*. The residue was triturated with ethyl acetate and diethyl ether to afford the title compound as a cream solid (0.42g).
TLC R_f 0.61 (50% ethyl acetate in hexane).

The following compounds were prepared in a similar manner.

10 **Intermediate 26** **7-Difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid 4-nitrophenyl ester**

Starting from 7-difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid (118mg). Purification by trituration with diethyl ether afforded the title compound as a pale yellow solid (83mg).

TLC R_f 0.54 (50% ethyl acetate in heptane).

15 **Intermediate 27** **7-Methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester**

Starting from 7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (1.16g). The title compound was obtained as a brown solid (1.76g).

TLC R_f 0.82 (5% methanol in dichloromethane).

20 **Intermediate 28** **7-Difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester**

Starting from 7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (0.3g). Purification by column chromatography on silica eluting with 50% ethyl acetate in heptane gave the title compound as a white solid (0.38g).

25 TLC R_f 0.55 (50% ethyl acetate in heptane).

Intermediate 29 **7-Methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester**

Starting from 7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid (0.3g). Purification by column chromatography on silica eluting with 50% ethyl acetate

30 in heptane gave the title compound as a cream solid (0.37g).

TLC R_f 0.48 (50% ethyl acetate in heptane).

Intermediate 30 **4-Chloro-2-methyl-2H-pyrazol-3-ylamine**

To a solution of 2-methyl-2H-pyrazol-3-ylamine (0.30g) in conc. hydrochloric acid (4ml) heated to 85°C was added dropwise hydrogen peroxide (0.67ml of a 30% solution in water). Heating continued for 60 mins. After cooling to 0°C the solution was taken to pH 11 using 46/48% w/w sodium hydroxide solution. The solid formed was filtered off and the filtrate extracted with ethyl acetate (4 x 50ml). The combined organic layers were dried over magnesium sulphate, filtered and concentrated *in vacuo*. The resulting product was combined with the previously collected product to afford the title compound as a brown solid (0.13g).

5 taken to pH 11 using 46/48% w/w sodium hydroxide solution. The solid formed was filtered off and the filtrate extracted with ethyl acetate (4 x 50ml). The combined organic layers were dried over magnesium sulphate, filtered and concentrated *in vacuo*. The resulting product was combined with the previously collected product to afford the title compound as a brown solid (0.13g).

10 TLC R_f 0.50 (10% methanol in dichloromethane).

Example 1 **7-Methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide**

To a stirred solution of 3,5-dimethylisoxazol-4-ylamine (88mg) in *N,N*-dimethylformamide (7ml) under an atmosphere of dry nitrogen at room temperature was added sodium bis(trimethylsilyl)amide (0.78ml, 1.0M solution in tetrahydrofuran). The reaction was stirred for 5 minutes. 7-Methoxy-2-(tetrahydro-furan-3-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester (200mg) was then added and stirring continued for 15 minutes. Water (1ml) was added and the solvent was removed *in vacuo*. The resulting residue was purified by column chromatography on silica eluting with 50% ethyl acetate in heptane followed by trituration with diethyl ether affording the title compound as a cream solid (52mg).

15 added sodium bis(trimethylsilyl)amide (0.78ml, 1.0M solution in tetrahydrofuran). The reaction was stirred for 5 minutes. 7-Methoxy-2-(tetrahydro-furan-3-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester (200mg) was then added and stirring continued for 15 minutes. Water (1ml) was added and the solvent was removed *in vacuo*. The resulting residue was purified by column chromatography on silica eluting with 50% ethyl acetate in heptane followed by trituration with diethyl ether affording the title compound as a cream solid (52mg).

20 in heptane followed by trituration with diethyl ether affording the title compound as a cream solid (52mg).

TLC R_f 0.60 (50% ethyl acetate in heptane).

Mp 183.5-185.2°C.

The following compounds were prepared in a similar manner.

25 **Example 2** **7-Difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (4-cyano-2-methyl-2-H-pyrazol-3-yl)-amide**

Prepared from 7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester (380mg) and 5-amino-1-methyl-1-H-pyrazole-4-carbonitrile (220mg). The reaction was stirred for 2 hours at room temperature. Water (1ml) was added and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (50ml) and washed with water (2x40ml), followed by 1N hydrochloric acid (40ml). The organic extract was dried over magnesium sulphate, filtered and preadsorbed onto

30 (1ml) was added and the solvent removed *in vacuo*. The residue was dissolved in ethyl acetate (50ml) and washed with water (2x40ml), followed by 1N hydrochloric acid (40ml). The organic extract was dried over magnesium sulphate, filtered and preadsorbed onto

silica. Purification by column chromatography on silica eluting with 70% ethyl acetate in heptane, followed by trituration with diethyl ether afforded the title compound as a white solid (170mg).

TLC R_f 0.63 (ethyl acetate).

5 Mass spectrum m/z 403 $[M+H]$.

Example 3 7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (5-cyano-3-methyl-3H-imidazol-4-yl)-amide

Prepared from 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid 4-nitrophenyl ester (250mg) and 5-amino-1-methyl-1-H-imidazole-4-carbonitrile (171mg). The reaction was stirred for 1 hour and 40 minutes. Water (1ml) was added and the solvent removed *in vacuo*. Purification by column chromatography on silica eluting with 10% methanol in dichloromethane afforded the title compound as a pale yellow solid (178mg). TLC R_f 0.35 (10% methanol in dichloromethane). Mass spectrum m/z 339 $[M-H]$

15 **Example 4** 7-Difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide

Prepared from 7-difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid 4-nitrophenyl ester (83mg) and 5-amino-1-methyl-1-H-pyrazole-4-carbonitrile (52mg) at 0°C. The reaction was stirred for 90 minutes at room temperature. Water (1ml) was added and the solvent removed *in vacuo*. Purification by column chromatography on silica eluting with 70% ethyl acetate in heptane, followed by trituration with diethyl ether afforded the title compound (21mg).

TLC R_f 0.35 (70% ethyl acetate in heptane).

Mp 118-120°C.

25 **Example 5** 7-Methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide

Prepared from 7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester (200mg) and 5-amino-1-methyl-1-H-pyrazole-4-carbonitrile (127mg) at 0°C. The reaction was stirred for 60 minutes at room temperature. Water (1ml) was added and the solvent removed *in vacuo*. Purification by column chromatography on silica eluting with 10% methanol in dichloromethane followed by gradient preparative HPLC on

a Phenomenex LUNA(2)TM C18 column eluting with 0.05% trifluoroacetic acid in 20%-65% acetonitrile in water afforded the title compound (19mg) as a white solid.

TLC R_f 0.47 (ethyl acetate).

Mp 186-188.8°C.

5 **Example 6** **7-Methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide**

Prepared from 7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid 4-nitrophenyl ester (370mg) and 5-amino-1-methyl-1-H-pyrazole-4 carbonitrile (122mg). The residue obtained from removing solvent *in vacuo* was dissolved in ethyl acetate (50ml) and washed with water (50ml) followed 1N hydrochloric acid (25ml). The organic extract
10 was dried over magnesium sulphate, filtered and preadsorbed onto silica. Purification by column chromatography on silica eluting with ethyl acetate afforded the title compound as a white solid (166mg).

TLC R_f 0.56 (ethyl acetate).

15 Mp 114.5-116°C.

Example 7 **7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide**

Oxalyl chloride (0.07ml) was added to a stirred solution of 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (100mg) in dry dichloromethane (20ml) at
20 room temperature under a dry nitrogen atmosphere. *N,N*-dimethylformamide (catalytic amount) was added and the reaction allowed to stir overnight. The solvent was removed *in vacuo* to afford the corresponding acid chloride as an oily yellow solid.

To a stirred solution of 5-amino-1-methyl-1-H-pyrazole-4-carbonitrile (155mg) in *N,N*-dimethylformamide (7ml) under an atmosphere of nitrogen at 0°C was added sodium
25 hydride (51mg, 60% dispersion in mineral oil). The reaction was stirred at 0°C for 5 minutes. A solution of the acid chloride in *N,N*-dimethylformamide (8ml) was added and the reaction stirred at room temperature for 2 hours. Water (1ml) was added and the solvent removed *in vacuo*. Purification by column chromatography on silica eluting with 1% methanol in dichloromethane followed by trituration with 50% diethyl ether in hexane
30 afforded the title compound as a pale yellow solid (4mg).

TLC R_f 0.52 (10% methanol in dichloromethane).

Mass spectrum m/z 339[M-H]

Example 8**7-Difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide**

Oxalyl chloride (0.09ml) was added to a stirred solution of 7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (0.15g) in dry dichloromethane (20ml) at room temperature under a dry nitrogen atmosphere. *N,N*-dimethylformamide (catalytic amount) was added and the reaction allowed to stir for 2 hours. The solvent was removed *in vacuo* to furnish the corresponding acid chloride as a yellow oil.

3,5-Dimethylisoxazol-4-ylamine (0.11g) was added to a stirred solution of the acid chloride in dry dichloromethane (30ml) at room temperature under a dry nitrogen atmosphere. Triethylamine (0.14ml) was added and the reaction allowed to stir at room temperature for 2 hours. The reaction was washed with water (30ml) and 1N hydrochloric acid (30ml). The organic phase was dried over magnesium sulphate, filtered and preadsorbed onto silica. Purification by column chromatography on silica eluting with 30% heptane in ethyl acetate yielded the title compound as a white solid (0.16g).

TLC R_f 0.17 (50% ethyl acetate in heptane)

Mp 155.5-156.5°C.

The following compounds were prepared in a similar manner.

Example 9**7-Methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide**

Starting from 7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid (262mg) and 3,5-dimethylisoxazol-4-ylamine (120mg). Purification by column chromatography on silica eluting with 30% ethyl acetate in hexane afforded the title compound as an off-white solid (238mg).

TLC R_f 0.36 (50% ethyl acetate in hexane)

Mass spectrum m/z 357 [M+H].

Example 10**7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide**

Starting from 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (0.19g) and 3,5-dimethylisoxazol-4-ylamine (88mg). Purification by column chromatography on silica eluting with ethyl acetate afforded the title compound as a cream solid (0.18g).

TLC R_f 0.17 (5% methanol in dichloromethane)

Mp 168.5-169.5°C.

Example 11**7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (4-chloro-2-methyl-2H-pyrazol-3-yl)-amide**

Starting from 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (0.14g) and 4-chloro-2-methyl-2H-pyrazol-3-ylamine (78mg). Purification by column chromatography on silica eluting with 50%-75% ethyl acetate in hexane afforded the title compound as an off white solid (34mg).

TLC R_f 0.57 (ethyl acetate)

Mp 158-160°C.

Example 12**7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (2-methyl-2H-pyrazol-3-yl)-amide**

Starting from 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (93mg) and 2-methyl-2H-pyrazol-3-ylamine (40mg). Purification by column chromatography on silica eluting with ethyl acetate afforded the title compound as a white solid (43mg).

TLC R_f 0.4 (ethyl acetate).

Mp 148-150°C.

Example 13**7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (2-ethyl-2H-pyrazol-3-yl)-amide**

Starting from 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (0.15g) and 2-ethyl-2H-pyrazol-3-ylamine (85mg). Purification by column chromatography on silica eluting with 50% ethyl acetate in heptane increasing to ethyl acetate afforded the title compound as a yellow solid (35mg).

TLC R_f 0.35 (ethyl acetate)

Mp 97-99°C.

Example 14**7-Methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (2,4-dimethyl-2H-pyrazol-3-yl)-amide**

Starting from 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (0.1g) and 2,4-dimethyl-2H-pyrazol-3-ylamine (56mg). Purification by column chromatography on silica eluting with 20% heptane in ethyl acetate and gradient preparative HPLC on a Phenomenex LUNA(2)TM C18 column eluting with 0.05% trifluoroacetic acid in 20%-65% acetonitrile in water gave the title compound as a pale yellow solid (39mg).

TLC R_f 0.33 (ethyl acetate)


Mass spectrum m/z 328 [M-H].

Example 15**7-Difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide**




- Cyanuric chloride (19mg) and triethylamine (0.05ml) were added to a stirred solution of 7-difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid (85mg) in dry dichloromethane at room temperature under a dry nitrogen atmosphere. After stirring for 20 minutes 3,5-dimethylisoxazol-4-ylamine (42mg) was added and the reaction left overnight. The reaction mixture was preadsorbed onto silica. Purification by column chromatography on silica eluting with 30% ethyl acetate in hexane gave the title compound as a cream solid (33mg)
- 10 TLC R_f 0.52 (50% ethyl acetate in hexane)
Mass spectrum m/z 367 $[M+H]$.

CLAIMS

1. A compound of the formula



- wherein R_1 is C_{1-3} alkyl optionally substituted with one or more fluorines;
 R_2 is CH_2OCH_3 or 2 or 3-tetrahydrofuranyl;
 R_3 is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C)



- R_4 is C_{1-3} alkyl; and
 R_5 and R_6 , which may be the same or different, each represents C_{1-3} alkyl, halogen, CF_3 or CN ;
or a pharmaceutically-acceptable salt thereof.

2. A compound of claim 1, wherein R_1 is CH_3 or CHF_2 .

3. A compound of claim 1 or claim 2, wherein R_3 is a pyrazole or isoxazole group.

4. A compound of claim 3, wherein R_3 is a pyrazole group, R_4 is CH_3 and R_5 is CN , CH_3 , Cl or CF_3 .

5. A compound of claim 3, wherein R_3 is an isoxazole group, R_5 is CH_3 , CF_3 or CN and R_6 is CH_3 , CF_3 or CN .

6. A compound of claim 1, selected from

7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide,

7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (4-cyano-2-methyl-2-H-pyrazol-3-yl)-amide,

7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (5-cyano-3-methyl-3H-imidazol-4-yl)-amide

5 7-difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide,

7-methoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide,

10 7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide,

7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (4-cyano-2-methyl-2-pyrazol-3-yl)-amide,

7-difluoromethoxy-2-(tetrahydrofuran-3-yl)-benzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide,

15 7-methoxy-2-(tetrahydrofuran-2-yl)-benzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide,

7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide,

20 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (4-chloro-2-methyl-2H-pyrazol-3-yl)-amide,

7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (2-methyl-2H-pyrazol-3-yl)-amide,

7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (2-ethyl-2H-pyrazol-3-yl)-amide,

25 7-methoxy-2-methoxymethylbenzofuran-4-carboxylic acid (2,4-dimethyl-2H-pyrazol-3-yl)-amide, and

7-difluoromethoxy-2-methoxymethylbenzofuran-4-carboxylic acid (3,5-dimethylisoxazol-4-yl)-amide.

7. A composition for use in therapy, comprising a compound of any preceding claim
30 and a pharmaceutically acceptable carrier or diluent.

8. Use of a compound of any of claims 1 to 6, for the manufacture of a medicament for use in the treatment of a disease state that is capable of being modulated by inhibition of phosphodiesterase IV or Tumour Necrosis Factor, or that is a pathological condition associated with a function of phosphodiesterase IV, eosinophil accumulation or a function of the eosinophil.
9. The use of claim 8, wherein the disease state is an inflammatory disease or autoimmune disease.
10. The use of claim 8, wherein the disease state is selected from asthma, chronic bronchitis, chronic pulmonary inflammatory disease, chronic obstructive airways disease, atopic dermatitis, allergic rhinitis, psoriasis, arthritis, rheumatoid arthritis, joint inflammation, ulcerative colitis, Crohn's disease, atopic eczema, stroke, bone resorption disease, multiple sclerosis and inflammatory bowel disease.
11. The use of claim 8, wherein the disease state is selected from urticaria, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, gouty arthritis and other arthritic conditions, adult respiratory distress syndrome, diabetes insipidus, keratosis, cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, depression, cardiac arrest, intermittent claudication, rheumatoid spondylitis, osteoarthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, cerebral malaria, silicosis, pulmonary sarcoidosis, reperfusion injury, graft vs host reaction, allograft rejection, infection-related fever or myalgia, malaria, HIV, AIDS, ARC, cachexia, keloid formation, scar tissue formation, pyresis, systemic lupus erythematosus, type 1 diabetes mellitus, Bechet's disease, anaphylactoid purpura nephritis, chronic glomerulonephritis, leukaemia, tarditive dyskinesia, yeast or fungal infection, conditions requiring gastroprotection, and neurogenic inflammatory disease associated with irritation and pain.
12. The use of claim 8, wherein the disease state is asthma.
13. The use of claim 8, wherein the disease state is chronic obstructive airways disease or chronic bronchitis.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00518

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D405/12 C07D413/12 C07D405/14 C07D413/14 A61K31/41
 A61K31/415 A61K31/42 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 44337 A (MONTANA JOHN GARY ;DYKE HAZEL JOAN (GB); CHIROSCIENCE LTD (GB); KE) 27 November 1997 (1997-11-27) cited in the application example 48	1-13
X	US 5 925 636 A (MONTANA JOHN GARY ET AL) 20 July 1999 (1999-07-20) cited in the application example 27	1-13
A	US 5 972 936 A (MONTANA JOHN GARY ET AL) 26 October 1999 (1999-10-26) cited in the application the whole document	1-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

25 April 2001

Date of mailing of the international search report

13/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Fritz, M

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/GB 01/00518

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MCGARRY D G ET AL: "BENZOFURAN BASED PDE4 INHIBITORS" BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, no. 6, 1999, pages 1131-1139, XP000978427 ISSN: 0968-0896 the whole document ----	1-13
A	WO 99 40085 A (DARWIN DISCOVERY LTD) 12 August 1999 (1999-08-12) the whole document ----	1-13
A	WO 96 03399 A (BYK GULDEN LOMBERG CHEM FAB ; ULRICH WOLF RUEDIGER (DE); THIBAUT UL) 8 February 1996 (1996-02-08) the whole document ----	1-13
A	WO 98 07715 A (BYK GULDEN LOMBERG CHEM FAB ; AMSCHLER HERMANN (DE)) 26 February 1998 (1998-02-26) the whole document -----	1-13

INTERNATIONAL SEARCH REPORT

Int. Application No.

PCT/GB 01/00518

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9744337 A	27-11-1997	AU 697976 B	22-10-1998
		AU 1038697 A	27-06-1997
		AU 2906097 A	09-12-1997
		BR 9611897 A	28-12-1999
		BR 9709113 A	03-08-1999
		CA 2238376 A	12-06-1997
		CN 1208411 A	17-02-1999
		CN 1219171 A	09-06-1999
		CZ 9801714 A	14-10-1998
		CZ 9803719 A	17-03-1999
		EP 0873331 A	28-10-1998
		EP 0901482 A	17-03-1999
		WO 9720833 A	12-06-1997
		JP 2000501411 T	08-02-2000
		JP 2000510848 T	22-08-2000
		NO 982570 A	04-08-1998
		NO 985375 A	19-11-1998
		PL 327181 A	23-11-1998
		PL 329912 A	26-04-1999
		SK 160498 A	11-06-1999
		TR 9802386 T	22-02-1999
		US 5773467 A	30-06-1998
		US 5925636 A	20-07-1999
		US 5972936 A	26-10-1999
US 5925636 A	20-07-1999	AU 697976 B	22-10-1998
		AU 1038697 A	27-06-1997
		AU 2906097 A	09-12-1997
		BR 9611897 A	28-12-1999
		BR 9709113 A	03-08-1999
		CA 2238376 A	12-06-1997
		CN 1208411 A	17-02-1999
		CN 1219171 A	09-06-1999
		CZ 9801714 A	14-10-1998
		CZ 9803719 A	17-03-1999
		EP 0873331 A	28-10-1998
		EP 0901482 A	17-03-1999
		WO 9720833 A	12-06-1997
		WO 9744337 A	27-11-1997
		JP 2000501411 T	08-02-2000
		JP 2000510848 T	22-08-2000
		NO 982570 A	04-08-1998
		NO 985375 A	19-11-1998
		PL 327181 A	23-11-1998
		PL 329912 A	26-04-1999
		SK 160498 A	11-06-1999
		TR 9802386 T	22-02-1999
		US 5773467 A	30-06-1998
		US 5972936 A	26-10-1999
US 5972936 A	26-10-1999	AU 697976 B	22-10-1998
		AU 1038697 A	27-06-1997
		AU 2906097 A	09-12-1997
		BR 9611897 A	28-12-1999
		BR 9709113 A	03-08-1999
		CA 2238376 A	12-06-1997
		CN 1208411 A	17-02-1999
		CN 1219171 A	09-06-1999

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00518

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5972936 A		CZ 9801714 A	14-10-1998
		CZ 9803719 A	17-03-1999
		EP 0873331 A	28-10-1998
		EP 0901482 A	17-03-1999
		WO 9720833 A	12-06-1997
		WO 9744337 A	27-11-1997
		JP 2000501411 T	08-02-2000
		JP 2000510848 T	22-08-2000
		NO 982570 A	04-08-1998
		NO 985375 A	19-11-1998
		PL 327181 A	23-11-1998
		PL 329912 A	26-04-1999
		SK 160498 A	11-06-1999
		TR 9802386 T	22-02-1999
		US 5773467 A	30-06-1998
		US 5925636 A	20-07-1999
WO 9940085 A	12-08-1999	AU 2529799 A	23-08-1999
		EP 1054884 A	29-11-2000
		US 6066657 A	23-05-2000
WO 9603399 A	08-02-1996	AT 196765 T	15-10-2000
		AU 702346 B	18-02-1999
		AU 3115395 A	22-02-1996
		CA 2195663 A	08-02-1996
		CN 1159804 A	17-09-1997
		CZ 9700188 A	17-09-1997
		DE 59508773 D	09-11-2000
		EP 0772610 A	14-05-1997
		ES 2152414 T	01-02-2001
		FI 970246 A	21-01-1997
		HU 77925 A	30-11-1998
		JP 10503484 T	31-03-1998
		NO 970092 A	09-01-1997
		NZ 290420 A	28-01-1999
		PL 318297 A	09-06-1997
		RU 2138498 C	27-09-1999
		SK 297 A	06-08-1997
		US 6121274 A	19-09-2000
WO 9807715 A	26-02-1998	AU 4454597 A	06-03-1998
		EP 0923568 A	23-06-1999
		JP 2000516932 T	19-12-2000

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)